Enliven Therapeutics Inc ELVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELVN is a good fit for your portfolio.
News
-
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
-
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
-
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
-
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
-
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
-
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $16.78
- Day Range
- $16.16–17.52
- 52-Week Range
- $9.80–26.00
- Bid/Ask
- $10.00 / $17.25
- Market Cap
- $804.12 Mil
- Volume/Avg
- 148,934 / 266,351
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 46
Comparables
Valuation
|
Metric
|
ELVN
|
VOR
|
TNGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.82 | 0.76 | 3.14 |
Price/Sales | — | — | 20.12 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELVN
|
VOR
|
TNGX
|
|---|---|---|---|
Quick Ratio | 9.78 | 8.81 | 7.33 |
Current Ratio | 10.28 | 9.04 | 7.54 |
Interest Coverage | — | — | — |
Quick Ratio
ELVN
VOR
TNGX
Profitability
|
Metric
|
ELVN
|
VOR
|
TNGX
|
|---|---|---|---|
Return on Assets (Normalized) | −24.03% | −41.83% | −21.14% |
Return on Equity (Normalized) | −29.30% | −51.69% | −35.54% |
Return on Invested Capital (Normalized) | −35.22% | −47.03% | −32.35% |
Return on Assets
ELVN
VOR
TNGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mjfcxsfcb | Fcqp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kycxtcrr | Hppqv | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pmjdxxldy | Yvcbk | $97.8 Bil | |
MRNA
| Moderna Inc | Cdyfrtvd | Dsgy | $41.3 Bil | |
ARGX
| argenx SE ADR | Nttdtnk | Mqxmc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ttkdvck | Qfzr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ygfvqjsbs | Yfzcp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wkrcxqvqs | Nnfnzzn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mtrxfkpmf | Ltjtpb | $12.5 Bil | |
INCY
| Incyte Corp | Qzplckjl | Bnxyrl | $11.6 Bil |